SCHEMBL10073159

SCHEMBL10073159

CCC(CC)NS(=O)(=O)c1n[nH]c2ncccc12

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
HTT P42858 2/20 0.35
GSK3A P49840 2/20 0.35
GSK3B P49841 2/20 0.35
NR3C1 P04150 5/20 0.34
PGR P06401 3/20 0.34
NR3C2 P08235 3/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
COMT P21964 1/20 0.33
MET P08581 1/20 0.33
FTO Q9C0B1 1/20 0.32
AURKA O14965 1/20 0.32
PARP1 P09874 1/20 0.32
GPR84 Q9NQS5 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073849 0.85 NR3C1 (0.36) ALDH1A1HTTGSK3AGSK3BNR3C1
SCHEMBL10073842 0.84 TDP1 (0.39) ALDH1A1HTTMAPTKDM4EMET
SCHEMBL10073639 0.82 MET (0.33) ALDH1A1HTTGSK3AGSK3BNR3C1
SCHEMBL10072912 0.82 NR3C1 (0.46) NR3C1PGRNR3C2
SCHEMBL10073459 0.81 SMN1; SMN2 (0.36) ALDH1A1HTTNR3C1
SCHEMBL10072911 0.81 UTS2R (0.39) ALDH1A1HTTGSK3AGSK3BNR3C1
SCHEMBL10073848 0.80 KMT2A (0.35) MAPTKDM4E
SCHEMBL10073652 0.80 ALDH1A1 (0.33) ALDH1A1GSK3AGSK3BNR3C1MAPT
SCHEMBL10073162 0.80 NR3C1 (0.42) ALDH1A1GSK3BNR3C1KDM4EHPGD
SCHEMBL12243475 0.76 MET (0.39) HTTGSK3AGSK3BMAPTMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-28 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
WO-2007059219-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases PRKDC, MAP3K20, PRKACA ALDH1A1 3237/4885HTT 2198/4885GSK3A 188/4885
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES PRKDC, MAP3K20, PRKACA ALDH1A1 3237/4885HTT 2198/4885GSK3A 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.